Case study: Management
A man in his 30s diagnosed with asthma at age 14 was experiencing poor control despite being on combination inhaler therapy (MART—Maintenance and Reliever Therapy). FeNO testing helped reveal issues with treatment adherence and inflammation control.
Last updated: September 2026
Gender/Age: Male in his 30s
History: Long-term asthma diagnosis, prescribed MART, using a combination inhaler twice daily with additional puffs as needed for symptom relief
TThe patient was adamant about taking his medication as prescribed, but pharmacy records showed he had only used four combination inhalers in the past year (when 12 were expected). He also filled four prescriptions for short-acting bronchodilators (SABAs), which is unusual for someone on MART, as MART therapy should reduce the need for additional SABAs.
Asthma Control Test (ACT): Scored 14, indicating poor control
FeNO Test: 87 ppb, indicating significant uncontrolled inflammation despite reported use of combination therapy
The high FeNO level made it clear that the patient’s inflammation was not controlled, suggesting poor adherence to his inhaler therapy.
The patient was shown the results, and this helped him understand the need for better adherence to his prescribed treatment.
FeNO testing provided an important insight into the patient’s uncontrolled inflammation and poor adherence to therapy. Sharing the results with the patient helped motivate him to improve his asthma management. This case highlights the importance of combining FeNO testing with patient education to improve treatment adherence and prevent unnecessary medication escalation.
Find more case study recomendations that you might like:
Request a quote for a device today with our simple and easy to use quotation tool. Used by thousands of healthcare professionals, NIOX® is the global device of choice for FeNO testing.
Request a Quote
At NIOX® we are passionate about providing excellent support and training.